Loading
How much the cancer cells still resemble the normal tissue they came from. Well-differentiated tumours look almost normal and tend to grow slowly; poorly differentiated ones have lost their identity and behave aggressively. It is the basis of grade.
Pathologists assign differentiation from gland formation, nuclear appearance and mitotic rate; it underlies grading systems such as Gleason (prostate), Nottingham (breast) and WHO grade for neuroendocrine tumours (well-differentiated NETs versus poorly differentiated neuroendocrine carcinomas, which are treated like small-cell cancer). Well-differentiated mucosal gastric cancers qualify for endoscopic resection; poorly differentiated thyroid cancer loses iodine uptake. Dedifferentiation over time (liposarcoma, thyroid, prostate to neuroendocrine) marks transformation to a more aggressive state.
Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.
Same organ: Glucagonoma, VIPoma, Somatostatinoma, Pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma), Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma (perihilar and distal), Biliary tract cancer (all types), Pancreatic neuroendocrine tumours, Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma, Gallbladder cancer, Gallbladder adenocarcinoma, Papillary carcinoma of the gallbladder, Mucinous carcinoma of the gallbladder, Adenosquamous and squamous carcinoma of the gallbladder, Neuroendocrine carcinoma of the gallbladder, Incidental gallbladder cancer (found after cholecystectomy), Carcinoma in situ and dysplasia of the gallbladder, Cystic duct carcinoma, Ampullary cancer (ampulla of Vater), Resectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic acinar cell carcinoma, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatoblastoma, Adenosquamous carcinoma of the pancreas, Colloid (mucinous non-cystic) carcinoma of the pancreas, Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma), Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma), Solid pseudopapillary neoplasm of the pancreas
Showing the organ this term concerns: Neuroendocrine tumours.
Shares Keratoacanthoma: the tumour that may be a squamous cell carcinoma, Adenocarcinoma, The subtype and grade on a cutaneous squamous cell carcinoma report, Histology.
Shares Cribriform growth pattern in prostate cancer, Dysplasia (pre-cancerous change), Prostate cancer.
Shares Keratoacanthoma: the tumour that may be a squamous cell carcinoma, The subtype and grade on a cutaneous squamous cell carcinoma report, Dysplasia (pre-cancerous change).
Shares Acinar adenocarcinoma of the prostate, Cribriform growth pattern in prostate cancer, Gleason score / Grade Group, Prostate cancer.
Shares Acinar adenocarcinoma of the prostate, Cribriform growth pattern in prostate cancer, Gleason score / Grade Group, Prostate cancer.
Shares Keratoacanthoma: the tumour that may be a squamous cell carcinoma, The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous, The subtype and grade on a cutaneous squamous cell carcinoma report.
Shares Cribriform growth pattern in prostate cancer, Gleason score / Grade Group, Prostate cancer.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.